FacebookTwitterGoogle+RedditEmail

Drug Companies and Health in China

Faced with declining prescription drug sales in the U.S., and having lost patent protection for many profitable drugs, the pharmaceutical industry is relying increasingly in new markets such as China and other fast-developing countries. The Economist Intelligence Unit estimates in $166 billion drug sales by 2017 in China, making of this country a natural market for companies looking for further growth. The revelation of corrupted practices, however, is a cause for concern.

In China, relationships between doctors and patients are under stress. One of the reasons is the unethical relations between many doctors and several drug companies. Although the practice of bribing doctors is not new in China, new allegations have surfaced recently against some well-known drug companies that demand new and more effective measures against this practice. According to some estimates, up to 30 percent of the cost of drugs is kicked back to doctors to increase sales.

There are several ways in which doctors are bribed by drug companies: they go from making cash payments and all-expenses-paid trips, to presents for their families and even “sexual favors.” Drug companies also bribe hospitals to stock their drugs so that doctors can prescribe them.

In addition to GlaxoSsmithKline, several other companies have been accused of rampant bribery, among them Eli Lilly, Pfizer, AstraZeneca, Sanofi, Novartis, Novo Nordisk and UCB. Both Eli Lilly and Pfizer have been accused of making illegal payments in China. The Swiss drug maker Novartis was also accused of bribing doctors to prescribe its anticancer drug Sandostatin LAR.

Some observers explain that doctors in China are prone to bribery due to the extremely low salaries they receive. For example, a doctor who is just out of medical school in Beijing earns approximately 3,000 yuan ($490) a month –including bonuses-, a salary that is equivalent to that of a taxi driver, and it is even lower for those in rural areas.

Not only drug companies bribe doctors, though. Oftentimes, patients bribe doctors to get procedures done, or done earlier. For some physicians, the main part of their salary comes from both patients and from drug companies’ bribes. Ministry of Health officials have been trying for years to put a stop to such practices, to no avail. According to some experts, some hospitals over treat and over examine patients to increase profits.

Under-the-table payments from patients to doctors are called “hongbao,” which is a reference to the cash-filled red envelopes given as presents during Lunar New Year festivities. These payments cover from jumping the queue for appointments to extra surgical fees.

Corruption extends far beyond the pharmaceutical industry and the health care system and encompasses many other aspects of Chinese market practices. According to some observers, bribing is a cultural behavior; you get things done according to the people you know. Particularly in the practice of medicine, it is a behavior that persists in detriment of people’s health. Chinese authorities are looking into bribing practices by 60 Chinese and foreign drug manufacturers.

Although the government cannot easily raise doctors’ salaries, since if would feel a similar pressure from all public sectors, regulating agencies should put a ceiling on drug prices, and make sure that these prices are not circumvented. More strict regulations should be established prohibiting doctors from accepting bribes and placing fines on companies which offer those bribes.

In the U.S., the Foreign Corrupt Practices Act bars companies from bribing foreign officials to gain business. In China, the Practicing Physicians Law, issued in 1999, forbids doctors from asking or illegally accepting money from their patients.

In China, an important step to make health care affordable to all citizens is to eliminate bribes to doctors for their services. In addition, as stated by the prestigious medical magazine The Lancet, “Training for doctors in China on managing their relationships ethically with the drug industry and other organizations should start at medical school and be part of continuing professional education.”

More articles by:

Dr. Cesar Chelala is a co-winner of the 1979 Overseas Press Club of America award for the article “Missing or Disappeared in Argentina: The Desperate Search for Thousands of Abducted Victims.”

December 19, 2018
Carl Boggs
Russophobia and the Specter of War
Jonathan Cook
American Public’s Backing for One-State Solution Falls on Deaf Ears
Daniel Warner
1968: The Year That Will Not Go Away
Arshad Khan
Developing Country Issues at COP24 … and a Bit of Good News for Solar Power and Carbon Capture
Kenneth Surin
Trump’s African Pivot: Another Swipe at China
Patrick Bond
South Africa Searches for a Financial Parachute, Now That a $170 Billion Foreign Debt Cliff Looms
Tom Clifford
Trade for Hostages? Trump’s New Approach to China
Binoy Kampmark
May Days in Britain
John Feffer
Globalists Really Are Ruining Your Life
John O'Kane
Drops and the Dropped: Diversity and the Midterm Elections
December 18, 2018
Charles Pierson
Where No Corn Has Grown Before: Better Living Through Climate Change?
Evaggelos Vallianatos
The Waters of American Democracy
Patrick Cockburn
Will Anger in Washington Over the Murder of Khashoggi End the War in Yemen?
George Ochenski
Trump is on the Ropes, But the Pillage of Natural Resources Continues
Farzana Versey
Tribals, Missionaries and Hindutva
Robert Hunziker
Is COP24 One More Big Bust?
David Macaray
The Truth About Nursing Homes
Nino Pagliccia
Have the Russian Military Aircrafts in Venezuela Breached the Door to “America’s Backyard”?
Paul Edwards
Make America Grate Again
David Rosnick
The Impact of OPEC on Climate Change
Binoy Kampmark
The Kosovo Blunder: Moving Towards a Standing Army
Andrew Stewart
Shine a Light for Immigration Rights in Providence
December 17, 2018
Susan Abulhawa
Marc Lamont Hill’s Detractors are the True Anti-Semites
Jake Palmer
Viktor Orban, Trump and the Populist Battle Over Public Space
Martha Rosenberg
Big Pharma Fights Proposal to Keep It From Looting Medicare
David Rosen
December 17th: International Day to End Violence against Sex Workers
Binoy Kampmark
The Case that Dare Not Speak Its Name: the Conviction of Cardinal Pell
Dave Lindorff
Making Trump and Other Climate Criminals Pay
Bill Martin
Seeing Yellow
Julian Vigo
The World Google Controls and Surveillance Capitalism
ANIS SHIVANI
What is Neoliberalism?
James Haught
Evangelicals Vote, “Nones” Falter
Vacy Vlanza
The Australian Prime Minister’s Rapture for Jerusalem
Martin Billheimer
Late Year’s Hits for the Hanging Sock
Weekend Edition
December 14, 2018
Friday - Sunday
Andrew Levine
A Tale of Two Cities
Peter Linebaugh
The Significance of The Common Wind
Bruce E. Levine
The Ketamine Chorus: NYT Trumpets New Anti-Suicide Drug
Jeffrey St. Clair
Roaming Charges: Fathers and Sons, Bushes and Bin Ladens
Kathy Deacon
Coffee, Social Stratification and the Retail Sector in a Small Maritime Village
Nick Pemberton
Praise For America’s Second Leading Intellectual
Robert Hunziker
The Yellow Vest Insurgency – What’s Next?
Nick Alexandrov
George H. W. Bush: Another Eulogy
Patrick Cockburn
The Yemeni Dead: Six Times Higher Than Previously Reported
Brian Cloughley
Principles and Morality Versus Cash and Profit? No Contest
Michael F. Duggan
Climate Change and the Limits of Reason
FacebookTwitterGoogle+RedditEmail